BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...
Nasdaq Staff determined that for the 10 consecutive business days between October 28 and November 11, 2024, the closing bid price of the Company’s ADSs has been at $1.00 per share or greater.
As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nas ...
As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with ...
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today ...
The agreement calls for BioNTech to pay Biotheus shareholders $800 million, largely in cash along with some of its American depositary shares. It will then pay up to $150 million in additional ...
Under the terms of the agreement, BioNTech will pay Biotheus shareholders an upfront consideration of $800 million, predominantly in cash, with a small portion in American depositary shares (“ADS”), ...
Ryanair Holdings (RYAAY) has released an update. Ryanair Holdings has announced a share buyback, purchasing and canceling a total of 233,539 shares, including ordinary shares and those underlying ...